

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids [ID872]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company(ies)</u></p> <ul style="list-style-type: none"> • Teva Pharmaceuticals (reslizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Against Allergy • Action for sick children • Allergy UK • Asthma UK • Black Health Agency • British Lung Foundation • Muslim Council of Britain • National Children's Bureau • South Asian Health Foundation • Specialised Healthcare Alliance • The Anaphylaxis Campaign <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Paediatric Respiratory Society • British Society for Allergy & Clinical Immunology • British Thoracic Society • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Asthma Relief Charity • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • NARA – The Breathing Charity • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Novartis (omalizumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Asthma, Allergy and Inflammation Research Trust • British Association for Lung Research • Cochrane Airways Group • MRC Clinical Trials Unit • National Institute for Health Research • National Society for Research into Allergy <p><u>Evidence Review Group</u></p>

National Institute for Health and Care Excellence
 Provisional matrix for the proposed technology appraisal of reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids [ID872]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Knowsley CCG • NHS St Helens CCG • Welsh Government 	<ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.